Related references
Note: Only part of the references are listed.STAT3 inhibition as a therapeutic strategy for leukemia
Rubashruti Kanna et al.
LEUKEMIA & LYMPHOMA (2018)
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Carlo Rinaldi et al.
NATURE REVIEWS NEUROLOGY (2018)
Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity
Seiichi Odate et al.
CLINICAL CANCER RESEARCH (2017)
FDA-Approved Oligonucleotide Therapies in 2017
Cy A. Stein et al.
MOLECULAR THERAPY (2017)
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Avi Ashkenazi et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
Sarah J. Ross et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Adam S. Sperling et al.
NATURE REVIEWS CANCER (2017)
Stem and progenitor cell alterations in myelodysplastic syndromes
Aditi Shastri et al.
BLOOD (2017)
Musashi-2 promotes migration and invasion in bladder cancer via activation of the JAK2/STAT3 pathway
Chenlu Yang et al.
LABORATORY INVESTIGATION (2016)
A 17-gene stemness score for rapid determination of risk in acute leukaemia
Stanley W. K. Ng et al.
NATURE (2016)
Treatment of low-risk myelodysplastic syndromes
Valeria Santini
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
Carolina Schinke et al.
BLOOD (2015)
Small molecule Mcl-1 inhibitors for the treatment of cancer
Johannes Belmar et al.
PHARMACOLOGY & THERAPEUTICS (2015)
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
David Hong et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
Moritz Gerstung et al.
NATURE COMMUNICATIONS (2015)
Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner
Shankar Varadarajan et al.
ONCOTARGET (2015)
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo
Petter S. Woll et al.
CANCER CELL (2014)
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Liran I. Shlush et al.
NATURE (2014)
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
Wendy W. Pang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia
Andres Jerez et al.
BLOOD (2012)
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS
Laura Barreyro et al.
BLOOD (2012)
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations
Britta Will et al.
BLOOD (2012)
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
Stefan P. Glaser et al.
GENES & DEVELOPMENT (2012)
Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia
Max Jan et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma
Anna Scuto et al.
CANCER RESEARCH (2011)
Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways
Ayumi Takakura et al.
HUMAN MOLECULAR GENETICS (2011)
Antisense Oligonucleotides Containing Conformationally Constrained 2′,4′-(N-Methoxy)aminomethylene and 2′,4′-Aminooxymethylene and 2′-O,4′-C-Aminomethylene Bridged Nucleoside Analogues Show Improved Potency in Animal Models
Thazha P. Prakash et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells
A. Pellagatti et al.
LEUKEMIA (2010)
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia
Michael G. Kharas et al.
NATURE MEDICINE (2010)
Short Antisense Oligonucleotides with Novel 2′-4′ Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals
Punit P. Seth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome
Benjamin L. Ebert et al.
PLOS MEDICINE (2008)
Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells
Ulrich Steidl et al.
NATURE GENETICS (2006)
Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I Interferons and transforming growth factor-β on normal hematopoiesis
A Verma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
A new mathematical model for relative quantification in real-time RT-PCR
MW Pfaffl
NUCLEIC ACIDS RESEARCH (2001)
Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression
PK Epling-Burnette et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Share Paper
